Skip to main content
PolicySpeak
← The ranking

Side by side

Compare organizations

Consultation participation and their own register declarations, side by side. Counts, not judgments — participation is not influence.

Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.

UNI
UNICANCER

NGO · France

2
files engaged
of 583 tracked
2
positions filed
in those 583 files
0.4
declared FTE
self-declared
0
EP accreditations
as declared to the register

Declared costs: €25K+ a year · in the register since 2021

EFP
EFPIA

Industry association · Belgium

35
files engaged
of 583 tracked
49
positions filed
in those 583 files
13.4
declared FTE
self-declared
13
EP accreditations
as declared to the register

Declared costs: €6M+ a year · in the register since 2009

Files both filed on (2)

Medicinal products for human use · European Health Data Space dataset descriptions

Register facts self-declared (snapshot 2 Sept 2026); cost bands are floors. Shared files are shared attention, not evidence of coordination.

What each said, in their own words

Their opening passages on the files they share, verbatim and in filing order. We do not summarize, compare, or characterize positions — read them at source.

Medicinal products for human use

EFPIA · filed 27 Apr 2021 · source

EFPIA supports an agile regulatory framework and a strong incentives’ system that embrace and encourage advances in science, technology & medicines. This evaluation is an opportunity to implement learnings from COVID-19 and ensure a competitive, world-class regulatory system in Europe supporting a globally competitive research-based industry at a critical time.

EFPIA · filed 3 Oct 2023 · source

EFPIA supports the objectives of enhancing the availability and accessibility of medicines, while fostering a competitive innovation environment in Europe. We welcome the proposal to future-proof the EU regulatory framework, maximising the use of expedited pathways, optimising regulatory decision-making processes, and reducing unnecessary administrative burdens.

EFPIA · filed 9 Oct 2023 · source

EFPIA supports the objectives of enhancing the availability and accessibility of medicines, while fostering a competitive innovation environment in Europe. We welcome the proposal to future-proof the EU regulatory framework, maximising the use of expedited pathways, optimising regulatory decision-making processes, and reducing unnecessary administrative burdens.

UNICANCER · filed 8 Nov 2023 · source

Unicancer, the French hospital federation of comprehensive cancer centers, expresses its gratitude to the European Commission for the opportunity to provide feedback in the public consultation on the legislative proposal for revising the EUs legislation on pharmaceuticals. While we welcome the proposal, we have five specific comments which we have integrated in the attached contribution: 1.

European Health Data Space dataset descriptions

EFPIA · filed 9 May 2026 · source

EFPIA welcomes the opportunity to comment on the draft Commission Implementing Act laying down the minimum metadata elements and their characteristics for dataset descriptions under the European Health Data Space (EHDS).

UNICANCER · filed 11 May 2026 · source

Out of the 180 HealthDCAT-AP properties reviewed in the Detailed Review sheet, 34 are recommended for inclusion in the minimum metadata set for data owners.The position is structured around six guiding principles : 1. Prefer controlled vocabularies over free text.

Take this comparison with you

2 organizations on one sheet: every file each filed on, their register declarations, and a working link to each submission. Free: we ask for your name and email, and PolicySpeak may contact you about the product (privacy policy). The per-file record stays downloadable without signing up on each file’s page.